drugset / Trial / NCT00403156
Imatinib Mesylate Combined With Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of study is to determine if Lucentis combined with imatinib mesylate will help treatment in patients with newly diagnosed choroidal neovascularization.
Timeline
- Start
- 2006-11
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Imatinib | Small molecule | 400 mg | — |
| Background | Ranibizumab | Monoclonal antibody | 0.5 mg | Intravitreal |